Australia's Leading Oncology Drug Compounder Chooses RIVA System
WINNIPEG, Canada, February 11 /PRNewswire/ -- Pharmatel Fresenius Kabi Pty Ltd, one of Australia's fastest growing and most innovative pharmaceutical companies, has chosen the RIVA System (Robotic IV Automation) - a self-contained unit for filling IV syringes and bags - from Intelligent Hospital Systems (IH Systems) to consolidate its IV preparation. Pharmatel Fresenius Kabi will take delivery of its first RIVA unit in June 2009.
The RIVA System and Pharmatel Fresenius Kabi's continued investment in specialized sterile facilities are a perfect match for meeting the needs of leading-edge oncology care providers, according to Kevin McGarry, Chief Executive Officer of IH Systems. "With two Therapeutic Goods Administration (TGA) registered aseptic compounding facilities preparing tailor-made chemotherapy doses each day, Pharmatel Fresenius Kabi knows this field and knows that the RIVA System is able to meet its very high standards," says Mr. McGarry. He continues, "We are thrilled to be working with this specialist company in oncology care."
As the demands for improving patient care and safety increase, health care facilities are increasingly seeking technologically advanced, cost efficient solutions, says Jane Arnot, Vice President of Sales and Marketing with IH Systems. "One of the many attributes of the RIVA System that makes it so attractive is its flexibility to support the diverse needs of Pharmatel Fresenius Kabi's clients," shares Ms. Arnot. "The RIVA System is well suited to compounding individual patient doses of oncology drugs into a range of diverse container forms including syringes and bags, which is key to supporting convenient and flexible therapy."
Limitations in conventional clean room technology have provided challenges for manufacturers of compounded oncology products, says Iain Rosekilly, Operations Director of Pharmatel Fresenius Kabi. "Since we identified the RIVA system, Intelligent Hospital Systems has worked tirelessly with us to develop the technology to fit our business model. Their flexible and customer centred approach will ensure the successful roll out and implementation of the project." Mr. Rosekilly continues, "IV Robotics have the ability to address our market growth requirements, as well as many of the important safety aspects involved in the aseptic compounding of IV drugs, this would include increased patient safety by the elimination of dose errors, furthermore providing increased technician operator safety, RSI and other OH& S factors."
RIVA (Robotic IV Automation System) - a self-contained unit for filling IV syringes and bags - is the first product developed by Winnipeg-based medical device company Intelligent Hospital Systems. For more information, please visit http://www.rivasystem.com.
For further information: Jane Arnot, VP Sales and Marketing, +1-204-925-5343
SOURCE Intelligent Hospital Systems
More by this Source
King Faisal Specialist Hospital & Research Centre Selects RIVA as IV Compounding Solution
24 Mar, 2014, 17:36 GMT
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Contact PR Newswire
Send us an email at MarketingUK@prnewswire.co.uk or call us at +44 (0)20 7454 5382
Become a PR Newswire client
Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382